Publications

Phase 1 Dose Escalation and Cohort Expansion Study Evaluating Safety, PK, PD and Clinical Activity of STC-15, a METTL3 Inhibitor in Patients with Advanced Malignancies, June 2024, ASCO Annual Meeting 2024

Justin C Moser¹, Kyriakos P Papadopoulos², Jordi Rodon Ahnert³, Yaara Ofir-Rosenfeld⁴, Josefin-Beate Holz⁴, STC15-22101 Study Team

¹HonorHealth Research Institute; ²START San Antonio; ³The University of Texas MD Anderson Cancer Center; ⁴Storm Therapeutics LTD

Download poster

Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL-3 inhibitor, in patients with advanced malignancies, Jun 2024, ASCO Annual Meeting 2024

Justin C Moser¹, Kyriakos P Papadopoulos², Jordi Rodon Ahnert³, Yaara Ofir-Rosenfeld⁴, Josefin-Beate Holz⁴, STC15-22101 Study Team

¹HonorHealth Research Institute; ²START San Antonio; ³The University of Texas MD Anderson Cancer Center; ⁴Storm Therapeutics LTD

Inhibiting coronavirus 5' RNA capping with potent, selective, FIC small molecules, May 2024, 4th SCI / RSC Symposium on Anti-Infectives Drug Discovery

Angela Glen¹ , Byron Andrews¹ , Ralph Baric^2a, Elliot Bayle¹ , Caitlin Duncan¹ , Matthew Fyfe¹ , Patrick Guest¹ , Helen Harrison¹ , Mark Heise^2b, Nat Moorman^2c, Oliver Rausch¹ , Trevor Scobey^2a, Tim Sheahan^2a, Chris Swain¹ , Sharon Taft-Benz^2b, Beth Thomas¹ , Aleksandra Zemla-Brown¹

¹STORM Therapeutics Ltd, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom

²AViDD-READDI, Rapidly Emerging Antiviral Drug Development Initiative (READDI): a) Department of Epidemiology, UNC Chapel Hill, Gillings School of Public Health; b) Department of Genetics, UNC Chapel Hill, School of Medicine; c) Department of Microbiology and Immunology, UNC Chapel Hill, School of Medicine

Download poster

STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment, Oct 2023, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Lina Vasiliauskaitė¹, Yaara Ofir-Rosenfeld¹, Mark Albertella¹, Coralie Hoareau-Aveilla², Jerry McMahon¹, Oliver Rausch¹

¹Storm Therapeutics Ltd., Cambridge, UK | ²Evotec SAS, Toulouse, FR

Download poster

STC-15, a novel METTL3 inhibitor, and its combination with Venetoclax confer anti-tumour activity in AML models, Jan 2023, American Association for Cancer Research (AACR) Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome

Lina Vasiliauskaitė¹, Yaara Ofir-Rosenfeld¹, Mark Albertella¹, Coralie Hoareau-Aveilla², Jerry McMahon¹, Oliver Rausch¹

¹Storm Therapeutics Ltd., Cambridge, UK | ²Evotec SAS, Toulouse, FR

STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses and synergizes with immune checkpoint blockade, Nov 2022, SITC Annual Meeting 2022

Joanna Obacz¹, Yaara Ofir-Rosenfeld¹, Lina Vasiliauskaitė¹, Claire Saunders^1*, Alexandra Sapetschnig¹, Georgia Tsagkogeorga^1,2, Mark Albertella¹⁺, Marie Carkill³, Jezrom Self-Fordham³, Josefin-Beate Holz¹, Oliver Rausch¹ and Jerry McMahon¹

¹Storm Therapeutics Ltd, Cambridge, UK | ²Milner Therapeutics Institute, University of Cambridge, Cambridge, UK | ³Charles River, Portishead, UK *Current address: UCL Cancer Institute, London, UK | ⁺Current address: Oncology R&D, AstraZeneca, Cambridge UK

STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergises with T cell checkpoint blockade, Oct 20

Yaara Ofir-Rosenfeld¹, Lina Vasiliauskaitė¹, Claire Saunders^1*, Alexandra Sapetschnig¹, Georgia Tsagkogeorga^1,2, Mark Albertella¹⁺, Marie Carkill³, Jezrom Self-Fordham³, Josefin-Beate Holz¹, Oliver Rausch¹ and Jerry McMahon¹

¹Storm Therapeutics Ltd, Cambridge, UK | ²Milner Therapeutics Institute, University of Cambridge, Cambridge, UK | ³Charles River, Portishead, UK | ^*Current address: UCL Cancer Institute, London, UK |⁺Current address: Oncology R&D, AstraZeneca, Cambridge UK

RNA uridyl transferases TUT4/7 differentially regulate miRNA variants depending on the cancer cell type, Mar 2022, RNA

Medhi R, Price J, Furlan G, Gorges B, Sapetschnig A, Miska EA.

28(3):353-370. doi: 10.1261/rna.078976.121. Epub 2021 Dec 23.PMID: 34949722

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia, May 2021, Nature

Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D, Hendrick AG, Webster NA, Andrews B, Fosbeary R, Guest P, Irigoyen N, Eleftheriou M, Gozdecka M, Dias JML, Bannister AJ, Vick B, Jeremias I, Vassiliou GS, Rausch O, Tzelepis K, Kouzarides T.

593(7860):597-601. doi: 10.1038/s41586-021-03536-w. Epub 2021 Apr 26.PMID: 33902106

Genome-wide investigation of gene-cancer associations for the prediction of novel therapeutic targets in oncology, Jul 2020, Sci Rep

Bazaga A, Leggate D, Weisser H.

10(1):10787. doi: 10.1038/s41598-020-67846-1.PMID: 32612205

A computational platform for high-throughput analysis of RNA sequences and modifications by mass spectrometry, Feb 2020, Nat Commun

Wein S, Andrews B, Sachsenberg T, Santos-Rosa H, Kohlbacher O, Kouzarides T, Garcia BA, Weisser H.

17;11(1):926. doi: 10.1038/s41467-020-14665-7.PMID: 32066737

RNA-modifying enzymes and their function in a chromatin context, Oct 2019, Nat Struct Mol Biol

Tzelepis K, Rausch O, Kouzarides T.

26(10):858-862. doi: 10.1038/s41594-019-0312-0. Epub 2019 Oct 3.PMID: 31582848

Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control, Dec 2017, Nature

Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millán-Zambrano G, Robson SC, Aspris D, Migliori V, Bannister AJ, Han N, De Braekeleer E, Ponstingl H, Hendrick A, Vakoc CR, Vassiliou GS, Kouzarides T.

552(7683):126-131. doi: 10.1038/nature24678. Epub 2017 Nov 27.PMID: 29186125

A call for direct sequencing of full-length RNAs to identify all modifications, Aug 2021, Nat Genet

Alfonzo JD, Brown JA, Byers PH, Cheung VG, Maraia RJ, Ross RL.

53(8):1113-1116. doi: 10.1038/s41588-021-00903-1.PMID: 34267373

The expanding world of tRNA modifications and their disease relevance, Jun 2021, Nat Rev Mol Cell Biol

Suzuki T.

22(6):375-392. doi: 10.1038/s41580-021-00342-0. Epub 2021 Mar 3.PMID: 33658722

m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy, Oct 2020, EMBO J

Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R, Yuan J, Rana TM.

39(20):e104514. doi: 10.15252/embj.2020104514. Epub 2020 Sep 23.PMID: 32964498

Role of RNA modifications in cancer, Jun 2020, Nat Rev Cancer

Barbieri I, Kouzarides T.

20(6):303-322. doi: 10.1038/s41568-020-0253-2. Epub 2020 Apr 16.PMID: 32300195

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade, Jan 2019, Nature

Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP, Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, Haining WN.

565(7737):43-48. doi: 10.1038/s41586-018-0768-9. Epub 2018 Dec 17.PMID: 30559380

The viral RNA capping machinery as a target for antiviral drugs, Oct 2012, Antiviral Res

Ferron F, Decroly E, Selisko B, Canard B.

96(1):21-31. doi: 10.1016/j.antiviral.2012.07.007. Epub 2012 Jul 26.PMID: 22841701